SequelSEC

Savara Inc SVRA

Pharmaceutical Preparations · CIK 0001160308 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$257.00K
Fiscal year ended 2020-12-31
Operating income
-$49.30M
Fiscal year ended 2020-12-31
Free cash flow
-$39.88M
Fiscal year ended 2020-12-31

Savara Inc (SVRA) reported revenue of $257.00K and net income of -$49.62M for the fiscal year ended 2020-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Savara Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Savara Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312017-12-312016-12-312015-12-312014-12-31
Revenue$257.00K$0$0$400.00K$54.00K$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$49.30M-$79.02M-$29.96M-$10.95M-$5.92M-$29.28M
Net income-$49.62M-$78.17M-$29.80M-$10.92M-$9.00M-$28.70M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$49.62M-$78.17M-$33.43M-$11.28M-$9.00M-$28.70M
Income tax expenseUnavailableUnavailable-$3.63M-$357.00K$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable$9.34M$10.96M$9.49M
General & administrative$14.26M$13.08M$11.08M$2.82M$1.65MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Savara Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312017-12-312016-12-312015-12-312014-12-31
Cash & equivalents$22.88M$49.80M$22.12M$13.37M$16.68M$12.69M
Total assets$97.74M$136.20M$159.63M$28.93M$54.22M$70.50M
Current assets$85.12M$124.07M$97.86M$14.61M$42.25M$58.40M
Total liabilities$33.36M$34.50M$40.32M$20.95M$30.33M$11.84M
Current liabilities$8.17M$10.88M$6.02M$3.46M$23.17M$8.44M
Total equity incl. NCI$942.00K-$17.00K$119.31M-$35.88M-$27.33M-$18.30M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable$43.86M$42.98M$20.27M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$0Unavailable$27.08M$3.05M$3.01M$3.01M
Long-term debt$25.10MUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.60M$3.41M$2.78M$536.00K$2.60M$1.37M

Cash flow

Savara Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$39.84M-$45.12M-$28.23MUnavailableUnavailableUnavailable
Capital expenditures$47.00K$148.00K$495.00K$8.00K$165.00K$147.00K
Investing cash flow$9.05M$15.74M-$69.12MUnavailableUnavailableUnavailable
Financing cash flow$3.69M$54.91M$106.09MUnavailableUnavailableUnavailable
Net change in cash-$26.92M$25.50M$8.75M-$3.31M$4.00M$10.13M
Stock-based compensation$5.11M$4.44M$552.00K$209.00K$153.00K$2.03M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$255.00K$311.00KUnavailable$99.00K$146.00K$85.00K

Derived

Savara Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312017-12-312016-12-312015-12-312014-12-31
Free cash flow-$39.88M-$45.27M-$28.73MUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-19182.9%UnavailableUnavailable-2737.0%-10968.5%Unavailable
FCF margin-15518.7%UnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue1987.2%UnavailableUnavailable52.2%283.3%Unavailable
Current ratio10.41x11.40x16.27x4.23x1.82x6.92x
Revenue YoY growthUnavailableUnavailable-100.0%640.7%UnavailableUnavailable
Net margin-19305.4%UnavailableUnavailable-2730.8%-16664.8%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue18.3%UnavailableUnavailable2.0%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SVRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 63441000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2019-12-31

Difference 101715000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2015-12-31

Difference 8232000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2014-12-31

Difference 56686000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.